FDA proposes $22 million in user fees

02/20/2006 | Boston Globe (tiered subscription model), The

The FDA has requested that Congress approve $22 million in new user fees to be paid by medical device and drug companies whose facilities require reinspection by the agency. Although the policy might encourage companies to clean up FDA violations in their plants more quickly, the reinspection fees could mean significant costs for the companies.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY